Dermatologic Therapy最新文献

{"title":"Efficacy and Safety of 30% Supramolecular Salicylic Acid and 10% Nicotinamide Combined Therapy in Melasma: A Randomized Placebo-Controlled Trial","authors":"Yu Zhu, Luyue Zhang, Dan Ye, Shiliu Huang, Huan Xue, Mengyao Yang, Zhao Wang, Weihui Zeng","doi":"10.1155/dth/9000703","DOIUrl":"https://doi.org/10.1155/dth/9000703","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Melasma is a prevalent dermatological condition characterized by hyperpigmented, asymmetrical brown patches with poorly defined borders. Nicotinamide (NAM), a derivative of vitamin B3, is widely recognized for its skin-lightening properties and demonstrates efficacy in melasma therapy. Supramolecular salicylic acid (SSA)–based chemical peels are a frequently employed therapeutic approach for managing melasma. This study evaluated the efficacy and safety of 30% SSA combined with 10% NAM in a randomized, double-blind, placebo-controlled trial in melasma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this randomized, double-blind, placebo-controlled trial, 56 patients with moderate-to-severe melasma were enrolled and randomized (1:1:1:1) to four groups (14 participants per group) of control, SSA, NAM, and SSA + NAM. Both assessors and participants were blinded. SSA treatment was given at an interval of 2 weeks for 8 treatment sessions (Weeks 0, 2, 4, 6, 8, 10, 12, 14). NAM was applied twice a day for 16 weeks. Clinical evaluations, including photographic documentation, mMASI scoring, and skin parameter measurements (transepidermal water loss [TEWL], skin hydration, melanin index [MI], erythema index [EI], red area score, and ultraviolet [UV] spot score), were assessed at 0, 2, 4, 6, 8,10,12, 14, and 16 weeks. Adverse events, therapeutic outcomes, and patient satisfaction levels were systematically documented.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifty-four patients completed all study procedures (control = 14, SSA = 13, NAM = 14, SSA + NAM = 13). All active treatments significantly reduced the mMASI compared with baseline. By Week 16, the SSA + NAM group achieved a 63.33% reduction in the mMASI, compared to 54.62% reduction in the SSA group and 59.55% in the NAM group. The reduction in mMASI scores in the SSA + NAM group was significantly greater than that in the SSA group, but was not significantly different from that in the NAM group. The combination group also showed a faster onset of improvement than the SSA group. Significant within-group improvements in red area score were observed in both SSA and SSA + NAM groups, while UV spot score decreased significantly only in the SSA + NAM group. TEWL, hydration, MI, and EI improved significantly in the active treatment groups at Week 16. Treatment-related adverse effects were mild and self-limiting, and no serious adverse events were observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Clinical results support the efficacy and safety of combined 30% SSA and NA","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9000703","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149048189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological Morbidity Is Associated with Quality-of-Life Impairment in Vitiligo Independent of Healthcare Setting: A Multivariable Analysis","authors":"Khushhal Farooqi, Mohammad Hashim Wafa, Abdul Razaq Hirman, Najibullah Fazli, Sharafuddin Resha, Sandesh Kumar Sharma","doi":"10.1155/dth/6309444","DOIUrl":"https://doi.org/10.1155/dth/6309444","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Vitiligo is a chronic skin condition characterized by depigmentation and is often linked to significant psychosocial challenges and reduced quality of life. However, the extent to which quality of life is influenced by disease severity versus psychological factors remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to explore the clinical and psychological factors associated with dermatology-related quality of life in patients with vitiligo and to assess whether healthcare setting was independently associated with quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study included 402 patients with vitiligo recruited from public and private hospitals in Kandahar, Afghanistan. Disease severity was assessed using the Vitiligo Area Scoring Index (VASI). Psychological distress was screened with the General Health Questionnaire-12 (GHQ-12); participants scoring ≥ 4 underwent further assessment with the Hamilton Anxiety Rating Scale (HAM-A) and the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16). Quality of life was measured using the Dermatology Life Quality Index (DLQI). Multivariable linear regression was conducted among all 402 participants to identify independent predictors of DLQI, with a secondary exploratory analysis among participants who screened positive for psychological distress.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The multivariable linear regression showed that psychological distress was independently associated with poorer dermatology-related quality of life (<i>B</i> = 0.963, 95% CI: 0.791–1.135, <i>p</i> < 0.001), whereas neither vitiligo severity (<i>B</i> = 0.025, <i>p</i> = 0.272) nor healthcare setting (<i>B</i> = −0.184, <i>p</i> = 0.498) remained significant after adjustment. The model explained 24.9% of the variance in quality-of-life scores. Of the 402 participants, 239 (59.5%) screened positive for psychological distress. Anxiety (<i>B</i> = 0.404, <i>p</i> < 0.001), depressive symptoms (<i>B</i> = 0.208, <i>p</i> < 0.001), and overall psychological distress (<i>B</i> = 0.385, <i>p</i> = 0.003) were independently associated with higher DLQI scores. In the secondary analysis, vitiligo severity showed a weaker association (<i>B</i> = 0.058, <i>p</i> = 0.005), whereas healthcare setting was not independently associated with quality-of-life impairment (<i>p</i> = 0.112). Sensitivity analysis excluding the influential observation with VASI = 80.30 produced similar estimates for psychological distress and hea","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6309444","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149047893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Light-Emitting Diode–Activated Gel Fluorescent Light Energy Therapy as Maintenance Treatment Following Aminolevulinic Acid Photodynamic Therapy for Severe Acne: A Case Report","authors":"Wenjiang Qian,&nbsp;Hongyi Zhao,&nbsp;Rongxin Ren","doi":"10.1155/dth/2771827","DOIUrl":"https://doi.org/10.1155/dth/2771827","url":null,"abstract":"<p>Severe acne frequently relapses after aminolevulinic acid photodynamic therapy (ALA-PDT), and adverse reactions such as erythema and dryness may limit tolerability. We report a 24-year-old woman with Grade IV acne treated with two ALA-PDT sessions followed by light-emitting diode–activated gel fluorescent light energy (FLE) therapy as posttreatment maintenance. FLE was applied twice weekly for six weeks. Compared with the discomfort of ALA-PDT (VAS: 7), FLE was painless (VAS: 0) and well tolerated during the maintenance phase. At 1 month after completion of the combined regimen, lesions continued to resolve with decreased erythema and porphyrin fluorescence on VISIA imaging, without relapse or adverse events. At 3- and 12-month follow-ups, clinical improvement was maintained, with progressive improvements in lesion counts and skin quality. This case illustrates the feasibility of incorporating FLE as a maintenance approach following ALA-PDT and highlights its potential clinical value in the management of severe acne.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/2771827","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149047892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Biologic Treatment of Atopic Dermatitis in Children: A Narrative Review of Dupilumab, Tralokinumab, and Lebrikizumab","authors":"Leen Heis,&nbsp;Diala Alshiyab,&nbsp;Firas Al-Qarqaz,&nbsp;Jihan Muhaidat,&nbsp;Hanadi Qeyam","doi":"10.1155/dth/1919917","DOIUrl":"https://doi.org/10.1155/dth/1919917","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Atopic dermatitis (AD) is a chronic inflammatory skin disease that frequently begins in childhood and can substantially impair sleep, psychosocial functioning, and quality of life. Biologic therapies targeting Type 2 inflammation have expanded treatment options for moderate-to-severe pediatric AD.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To synthesize current evidence on dupilumab, tralokinumab, and lebrikizumab in pediatric and adolescent AD using a narrative review design supported by a systematized literature search.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;PubMed/MEDLINE, Scopus, the Cochrane Library, and supplementary Google Scholar citation tracking were searched for the literature from January 1, 2015, to May 31, 2026, with the search rerun on July 1, 2026. Eligible evidence included randomized controlled trials, open-label extensions, post hoc analyses, observational cohorts, and real-world studies evaluating efficacy, safety, pruritus, quality of life, IGA, EASI, EASI-75, EASI-90, adverse events, or discontinuation. Meta-analysis was not performed because of heterogeneity in age groups, biologic agents, background topical corticosteroid use, endpoint definitions, follow-up duration, and study design (Page et al., 2021, Sterne et al., 2016, Sterne et al., 2019). This article is a narrative review; it was not registered, and no formal risk-of-bias scoring, GRADE certainty rating, or quantitative synthesis was undertaken.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Dupilumab has the broadest pediatric evidence base, including randomized and extension data in young children and adolescents. Tralokinumab evidence is concentrated in adolescents, with ECZTRA 6 providing the central randomized evidence. Lebrikizumab evidence is also adolescent-focused and growing, with supportive Phase 3 and extension data. Safety findings were considered separately; conjunctivitis, injection-site reactions, nasopharyngitis/URTI, serious adverse events, and discontinuation were variably reported across trials, extensions, and real-world studies. Because the included studies differed in population, age band, background topical therapy, endpoint definition, and follow-up duration, response rates are reported descriptively and are not comparable across agents.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Biologic therapies are important targeted options for moderate-to-severe pediatric AD, but the maturity of the evidence ","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1919917","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149047862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Skin Clearance: Cardiovascular Health Improvements in Atopic Dermatitis Patients Treated With Upadacitinib","authors":"Marco Manfredini,&nbsp;Laura Bonzano,&nbsp;Alessandro Borghi,&nbsp;Andrea Conti,&nbsp;Vito Di Lernia,&nbsp;Mario Bruno Guanti,&nbsp;Carlotta Gurioli,&nbsp;Andrea Marani,&nbsp;Gionathan Orioni,&nbsp;Francesca Satolli,&nbsp;Natale Schettini,&nbsp;Caterina Longo","doi":"10.1155/dth/3352818","DOIUrl":"https://doi.org/10.1155/dth/3352818","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>JAK inhibitors raised concerns about potential cardiovascular and metabolic effects based on heterogeneous safety signals and evolving evidence. We investigated whether upadacitinib for the treatment of atopic dermatitis patients is associated with concurrent changes in lifestyle and cardiovascular health as measured by the American Heart Association Life’s Essential 8.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective observational study included 124 adults treated with upadacitinib 15 mg or 30 mg once daily at six Italian dermatology units between 1 April 2022 and 1 December 2025. Data from electronic records at baseline, Week 4, Week 16 and Week 32 comprised EASI, NRS-itch, DLQI, sleep duration, self-reported moderate-to-vigorous physical activity, smoking status, weight, blood pressure, fasting glucose, non-HDL cholesterol and diet assessed with the 9-item Mini-EAT questionnaire. Longitudinal changes were evaluated with the Friedman test and linear mixed models with random intercepts; adjusted models included age, disease onset and biologic-naïve status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>EASI and NRS-itch showed rapid, sustained reductions, and DLQI improved markedly. Sleep duration increased by Week 16. Self-reported physical activity rose substantially. Mini-EAT fruit scores and intakes of legumes, nuts, seeds and seafood increased while saturated fat intake declined. The composite LE8 score increased over follow-up. Non-HDL cholesterol showed a modest upward trend.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>In this real-world cohort, upadacitinib was associated with pronounced skin improvement and parallel, clinically relevant gains in diet, sleep and physical activity that increased LE8 scores and may counterbalance the observed modest increase in non-HDL cholesterol, although prospective studies are needed to determine net cardiovascular effects.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3352818","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149047863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Landscape of Skin Cancer Prevention: A European Survey of Dermatologists’ Practices","authors":"Marek Jankowski,&nbsp;Andrea Carugno","doi":"10.1155/dth/8995523","DOIUrl":"https://doi.org/10.1155/dth/8995523","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The global incidence of keratinocyte carcinomas (KCs) is consistently rising. While consensus-based guidelines for active chemoprevention exist (recommending modalities such as oral acitretin, nicotinamide, and photodynamic therapy), their real-world adoption and the rationales driving European dermatologists’ therapeutic choices remain largely unclear.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To evaluate the real-world adoption rates, therapeutic preferences, and underlying decision-making rationales of European dermatologists regarding the active prevention of KCs.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A web-based survey was distributed to 9469 active European dermatologists. The survey assessed the frequency of preventive practices, treatment rankings, and the importance of various rationales (e.g., scientific evidence, familiarity, legal status, and affordability) for both adopting and rejecting specific methods.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Data from 1274 respondents for primary prevention and 517 for secondary prevention (20.1% response rate) were analyzed. Approximately 25% of practitioners seldom or almost never offer active prevention, with significant intercountry variability (&lt;i&gt;p&lt;/i&gt; &lt; 0.001). Topical imiquimod emerged as the most popular preventive method, largely outpacing guideline-endorsed systemic options. “Scientific evidence” was the primary rationale for adopting a therapy, whereas “lack of familiarity” was the leading reason for rejection, particularly concerning oral nicotinamide. Lack of access and off-label legal status acted as major deterrents, while potential profitability was the least significant decision factor. A previous KC diagnosis was accompanied by a higher reported frequency of offering active prevention, but we found no evidence that it altered the underlying rationale for method selection.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Among the participating EADV-affiliated dermatologists, there is a marked discrepancy between current KC chemoprevention guidelines and everyday clinical practice. The preference for topical field therapies over systemic agents is prevalent in this cohort. To optimize healthcare resources and effectively change clinical behavior, efforts must go beyond raising awareness; they must focus on revising educational curricula, improving drug accessibility, and clarifying labeling regulations.&lt;/p&gt;\u0000 &lt;/sectio","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8995523","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149047864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 6-Month Open-Label Clinical Study Evaluating Hair and Skin Parameters After Daily Intake of a Multifactorial Drinkable Nutraceutical in Menopausal and Postmenopausal Women With Female Pattern Hair Loss","authors":"Manuel Sáez Moya,&nbsp;Alba Gómez-Zubiaur,&nbsp;Gillian E. Westgate","doi":"10.1155/dth/7146666","DOIUrl":"https://doi.org/10.1155/dth/7146666","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Introduction&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Female pattern hair loss (FPHL) is a multifactorial condition whose prevalence increases with advancing age. Its pathogenesis in menopausal and postmenopausal women is complex, involving multiple factors such as oxidative stress and hormonal changes that may contribute to progressive impairment of hair quality and psychosocial well-being.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This 6-month open-label, single-arm proof-of-concept clinical study evaluated tolerability and within-subject changes in hair and skin parameters following daily intake of a drinkable nutraceutical formulated to support FPHL and hair aging in menopausal and postmenopausal women.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Thirty-nine healthy menopausal women (including postmenopausal) (50–65 years; Ludwig I) received one 25-mL vial daily for 6 months. The primary endpoint was the increase in hair density from baseline at 6 months (D180), assessed by phototrichoscopy (HairMetrix Canfield). Secondary endpoints included hair shedding, hair coverage, skin-related parameters, and tolerability.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Daily oral supplementation was well tolerated, and a statistically significant within-subject increase from baseline was observed in hair density by 11.26 hairs/cm&lt;sup&gt;2&lt;/sup&gt; at D90 and 18.87 hairs/cm&lt;sup&gt;2&lt;/sup&gt; at D180 (&lt;i&gt;p&lt;/i&gt; &lt; 0.001). Hair shedding decreased by 42.40%, and hair coverage area increased by 11.24% at D180 (&lt;i&gt;p&lt;/i&gt; &lt; 0.0001). Changes from baseline in skin-related parameters such as hydration and brightness were also observed.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This open-label, single-arm proof-of-concept study suggests that daily intake of the multifactorial drinkable nutraceutical was associated with within-subject changes over time, including increases in hair density, reductions in hair shedding, and changes in selected skin-related parameters, in menopausal women (including postmenopausal) with FPHL. These findings highlight the potential of a multifactorial nutraceutical approach targeting hair and skin changes during menopause. While these preliminary results are encouraging, they arise from an uncontrolled study design, and larger randomized, double-blind, placebocontrolled trials are required to corroborate these findings and further explore the underlying biological mechanisms.&lt;/p&gt;\u0000 \u0000 &lt;p&gt;&lt;b&gt;Trial Registration:&lt;/b&gt; Clinical trial.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7146666","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149047833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-Wavelength Diode Laser (810 nm and 940 nm) for Rosacea: A Retrospective Study","authors":"Xinyi Xie,&nbsp;Jiaoquan Chen,&nbsp;Yeqing Gong,&nbsp;Fengyi Chen,&nbsp;Yiling Wu,&nbsp;Shiqi He,&nbsp;Huilan Zhu,&nbsp;Shaoyin Ma","doi":"10.1155/dth/3155196","DOIUrl":"https://doi.org/10.1155/dth/3155196","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the efficacy, safety, and influencing factors of an 810- and 940-nm diode laser (MeDioStarNeXT) for treating rosacea.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective study included 289 patients with rosacea who received an 810- and 940-nm diode laser (energy density of 28–34 J/cm², 150–200 ms, a speed of 1.5 Hz, and a dual pulse) treatment at Guangzhou Dermatology Hospital between December 2017 and December 2025. Disease severity was assessed using the Clinician Erythema Assessment (CEA) scale and the Investigator’s Global Assessment (IGA). The primary outcome measure for efficacy analysis was the IGA improvement rate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 289 patients, 3 cases (1.04%) achieved cured (≥ 90% improvement), 45 cases (15.57%) showed excellent (60%–89% improvement), 151 cases (52.25%) were classified as effective (20%–59% improvement), and 90 cases (31.14%) were ineffective (&lt; 20% improvement), yielding an overall effective rate of 68.86%. Post-treatment CEA and IGA scores were significantly improved compared to baseline (<i>p</i> &lt; 0.001). Univariate analysis revealed that only the number of treatment sessions was significantly correlated with treatment efficacy (<i>p</i> &lt; 0.001). Multivariate logistic regression analysis indicated that shorter disease duration and a higher number of treatment sessions were significantly associated with better treatment outcomes (<i>p</i> &lt; 0.05). No significant correlations were observed between efficacy and sex, age, Fitzpatrick skin type, or rosacea subtype (<i>p</i> &gt; 0.05). No severe adverse reactions occurred. The main events were transient erythema (74.7%), moderate pain (70.0%), and edema (28.4%), all resolving within 24 h.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A diode laser (810 and 940 nm) is safe and may be effective for rosacea. Treatment efficacy is influenced by the number of treatments and timing of intervention. However, given the single-center retrospective design of this study, these findings warrant further validation in prospective randomized controlled trials.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3155196","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149047835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Clinical, Confocal, and Microbial Changes in Facial Skin After a Professional Chemical Peel","authors":"Shazli Razi,&nbsp;Vinay Bhardwaj,&nbsp;Thu Minh Truong,&nbsp;Samantha Ouellette,&nbsp;Morgan Ulczak,&nbsp;Junhong Mao,&nbsp;Babar k. Rao","doi":"10.1155/dth/2352860","DOIUrl":"https://doi.org/10.1155/dth/2352860","url":null,"abstract":"<p>Chemical peeling is a popular cutaneous resurfacing procedure for photoaging, fine lines, scarring, pigmentary disorders, wrinkles, and inflammatory dermatoses. We conducted a clinical pilot study with 18 subjects, involving initial screening, two peeling sessions, and a postpeel assessment. We used a combination peel containing 10% TCA and 24% lactic acid, with a pH ranging from 0.15 to 1.15. Subjects underwent clinic visits for cheek swabbing for microbial analysis, dermatologist assessment, VISIA imaging, and confocal microscopy at 4-week intervals. Results: The score for global appearance, abnormal pigmentation, and fine and coarse wrinkling were assessed on a scale ranging from 0 (<i>absent</i>) to 9 (<i>severe</i>), with the following subscales: 1–3: mild, 4–6: moderate, and 7–9: severe. The average score for global appearance improved from 5 to 3.5, wrinkles from 4.5 to 3.5, and uneven pigmentation from 4.75 to 3.5. VISIA analysis showed an improvement in spots, brown spots, texture, pores, and red areas. Confocal microscopy showed a decrease in melanin and an increase in collagen. Microbial analysis indicated no imbalance in the microflora of the facial skin; counterintuitively, there was a trend showing an increase in species diversity after each peeling session as seen in Shannon diversity, Hill1 diversity, and observed taxonomic units. The facial peel was well tolerated and was effective in improving overall global appearance, uneven pigmentation, and wrinkles.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/2352860","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148994368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing Dermatological Care Disparities Through Synchronous Teledermatology: Insights From Psychiatric Hospital and Long-Term Care Facility in the Tropics","authors":"Han-Chi Tseng,&nbsp;Chia-Ying Wu,&nbsp;Po-Ta Lai,&nbsp;Chih-Che Lin,&nbsp;Chih-Hung Lee","doi":"10.1155/dth/9987886","DOIUrl":"https://doi.org/10.1155/dth/9987886","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and objectives</h3>\u0000 \u0000 <p>Telemedicine provides prompt services for patients in need. Synchronous video teledermatology to serve psychiatric (PSY) inpatients and long-term care (LTC) facility was rarely discussed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and methods</h3>\u0000 \u0000 <p>This retrospective observational study explores the feasibility of weekly synchronous video teledermatology consultations at Kaohsiung Chang Gung Memorial Hospital to Hualien Yuli Hospital (HLYLH, a PSY hospital) and Taitung Hospital Cheng-Kung Branch (THCKB, with a LTC facility) from August 2021 to August 2023.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>About 92 patients (21 from LTC) had 271 visits at THCKB, and 230 patients (219 PSY patients) had 833 visits at HLYLH. The mean age was 62.0 and 62.4 years in HLYLH and THCKB, respectively. Eczema was the leading diagnosis, identified in 159/219 PSY patients (72.6%) at HLYLH and 14/21 LTC residents (66.7%) at THCKB. Dermatophyte infections were significantly more common in LTC residents than PSY (13/21, 61.9% vs. 16/219, 7.3%, <i>p</i> &lt; 0.001), whereas scabies was more prevalent in PSY compared to LTC residents (43/219, 19.6% vs. 2/21, 9.5%, <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Eczema is the most common dermatosis identified in LTC residents and PSY in the synchronous teledermatology. The synchronous teledermatology consultation provided prompt delivery of professional care for PSY patients in the PSY hospital and elderly residents in LTC facility.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9987886","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148994414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}